Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

14,987 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Differences among patients with and without nonalcoholic fatty liver disease having elevated alanine aminotransferase levels at various stages of metabolic syndrome.
Sogabe M, Okahisa T, Kurihara T, Takehara M, Kagemoto K, Okazaki J, Kida Y, Hirao A, Tanaka H, Tomonari T, Taniguchi T, Okamoto K, Nakasono M, Takayama T. Sogabe M, et al. Among authors: tanaka h. PLoS One. 2020 Aug 31;15(8):e0238388. doi: 10.1371/journal.pone.0238388. eCollection 2020. PLoS One. 2020. PMID: 32866186 Free PMC article.
MiR-125b-5p Is Involved in Sorafenib Resistance through Ataxin-1-Mediated Epithelial-Mesenchymal Transition in Hepatocellular Carcinoma.
Hirao A, Sato Y, Tanaka H, Nishida K, Tomonari T, Hirata M, Bando M, Kida Y, Tanaka T, Kawaguchi T, Wada H, Taniguchi T, Okamoto K, Miyamoto H, Muguruma N, Tanahashi T, Takayama T. Hirao A, et al. Among authors: tanaka t, tanaka h. Cancers (Basel). 2021 Sep 30;13(19):4917. doi: 10.3390/cancers13194917. Cancers (Basel). 2021. PMID: 34638401 Free PMC article.
Therapeutic efficacy of lenvatinib in nonviral unresectable hepatocellular carcinoma.
Tomonari T, Sato Y, Tanaka H, Mitsuhashi T, Hirao A, Tanaka T, Taniguchi T, Okamoto K, Sogabe M, Miyamoto H, Muguruma N, Takayama T. Tomonari T, et al. Among authors: tanaka t, tanaka h. JGH Open. 2021 Oct 22;5(11):1275-1283. doi: 10.1002/jgh3.12663. eCollection 2021 Nov. JGH Open. 2021. PMID: 34816013 Free PMC article.
Initial therapeutic results of atezolizumab plus bevacizumab for unresectable advanced hepatocellular carcinoma and the importance of hepatic functional reserve.
Tomonari T, Tani J, Sato Y, Tanaka H, Tanaka T, Taniguchi T, Asahiro M, Okamoto K, Sogabe M, Miyamoto H, Muguruma N, Masaki T, Takayama T. Tomonari T, et al. Among authors: tanaka t, tanaka h. Cancer Med. 2023 Feb;12(3):2646-2657. doi: 10.1002/cam4.5145. Epub 2022 Aug 14. Cancer Med. 2023. PMID: 35964253 Free PMC article.
Multicenter retrospective study of initial treatment outcome and feasibility of initiating dose reduction of cabozantinib in unresectable hepatocellular carcinoma.
Tomonari T, Tani J, Ogawa C, Deguchi A, Senoh T, Moriya A, Shibata H, Fukuno H, Tanaka H, Tanaka T, Taniguchi T, Sogabe M, Kawano Y, Morishita A, Takaguchi K, Miyamoto H, Sato Y, Masaki T, Takayama T. Tomonari T, et al. Among authors: tanaka t, tanaka h. Hepatol Res. 2023 Feb;53(2):172-178. doi: 10.1111/hepr.13845. Epub 2022 Oct 18. Hepatol Res. 2023. PMID: 36214071
A case of complete response with rechallenge-lenvatinib plus transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma refractory to multiple molecular-targeted agent treatments.
Tomonari T, Tanaka H, Tanaka T, Taniguchi T, Sogabe M, Kawano Y, Okamoto K, Miyamoto H, Sato Y, Takayama T. Tomonari T, et al. Among authors: tanaka t, tanaka h. Clin J Gastroenterol. 2023 Jun;16(3):438-443. doi: 10.1007/s12328-023-01777-y. Epub 2023 Mar 1. Clin J Gastroenterol. 2023. PMID: 36856957
14,987 results
You have reached the last available page of results. Please see the User Guide for more information.